肌层浸润性膀胱癌新辅助化疗的自身不足与应用局限  

Disadvantages and limitations of neoadjuvant chemotherapy for invasive bladder cancer

作　　者：黄海 胡欣芫 陈国俊[2] 任海林[2] HUANG Hai;HU Xinyuan;CHEN Guojun;REN Hailin(Graduate School of Qinghai University,Xining 810000;Department of Urology,Affiliated Hospital of Qinghai University,Xining 810000,China)

机构地区：[1]青海大学研究生院,青海西宁810000 [2]青海大学附属医院泌尿外科,青海西宁810000

出　　处：《现代泌尿外科杂志》2024年第11期1021-1025,共5页Journal of Modern Urology

基　　金：青海大学附属医院中青年科研基金(No.ASRF-2011-14)。

摘　　要：对于肌层浸润性膀胱癌(MIBC)患者,术前新辅助化疗(NAC)可使肿瘤降期、治疗微转移灶,有效延长患者的中位生存期,改善预后。然而,NAC本身存在肾功能损害、血栓栓塞、药物毒副作用等不足,其治疗效果受到肿瘤病理类型、DNA修复基因缺陷、是否原发MIBC、TNM分期等因素的影响,故使用上存在一定的局限性。基于顺铂治疗的方案,越来越多的研究开始探索NAC在MIBC治疗方案的局限性和缺陷。本文对NAC的不足及其在MIBC治疗中的应用进行概述和展望。For muscle-invasive bladder cancer(MIBC)patients,preoperative neoadjuvant chemotherapy(NAC)can reduce the tumor stage,treat micrometastases,prolong the median survival,and improve the prognosis.However,NAC is associated with side effects such as renal impairment,thromboembolism and drug toxicity.NAC itself suffers from deficiencies such as renal function impairment,thromboembolism,and drug toxicity.Its therapeutic efficacy is affected by factors such as tumor pathology type,DNA repair gene defects,whether it is primary MIBC,and TNM staging,so there are certain limitations in its use.Based on the cisplatin treatment regimen,more and more studies are exploring the limitations and shortcomings of NAC in MIBC treatment regimen.Therefore,this paper provides an overview and outlook of the application of NAC in MIBC treatment.

关 键 词：肌层浸润性膀胱癌 顺铂 新辅助化疗 根治性膀胱切除术 缺陷 

分 类 号：R737.14[医药卫生—肿瘤]